2023
Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
Phillips M, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, Neuzil K, Gordon M, Thindwa D, Paltiel A, Yaesoubi R, Pitzer V. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. BMC Infectious Diseases 2023, 23: 143. PMID: 36890448, PMCID: PMC9993384, DOI: 10.1186/s12879-023-08105-2.Peer-Reviewed Original ResearchConceptsTyphoid Conjugate VaccineRoutine vaccinationReactive vaccinationVaccination strategiesOutbreak settingsMultidrug-resistant Salmonella typhiQueen Elizabeth Central HospitalTyphoid fever epidemicYears of ageMonths of ageCost-effectiveness analysisWorld Health OrganizationConjugate vaccineCentral HospitalRoutine immunizationVaccine deploymentPreventive vaccinationVaccinationTyphoid feverCost-effective strategyAge 15Health OrganizationFever epidemicAntimicrobial resistanceOutbreak definitions
2022
Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness
Burrows H, Antillón M, Gauld J, Kim J, Mogasale V, Ryckman T, Andrews J, Lo N, Pitzer V. Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness. Vaccine 2022, 41: 965-975. PMID: 36586741, PMCID: PMC9880559, DOI: 10.1016/j.vaccine.2022.12.032.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioRoutine vaccinationVaccine impactPublic health impactOne-time catchPotential public health impactHigh-incidence settingsTyphoid fever casesCost-effectiveness ratioMonths of ageHealth impactsModel-predicted outcomesPrimary outcomeChronic carriersIncidence settingsSymptomatic casesVaccine introductionEndemic settingsVaccine deploymentFever casesVaccinationTyphoid casesIncremental costTyphoid transmissionMonths